Treatment of Ankylosing Spondylitis
Ankylosing spondylitis is a type of inflammatory arthritis primarily affecting the spine and sacroiliac joints. It causes chronic pain and stiffness in the lower back and can lead to fusion of spinal vertebrae. It is more common in men.
Managing Ankylosing Spondylitis effectively requires a combination of medical treatment, lifestyle modification, and regular monitoring. With a structured management plan, most people with Ankylosing Spondylitis can maintain a good quality of life and prevent serious complications.
First-Line Treatment Principles
- ✓Treat-to-target (T2T) strategy in RA and SpA: aim for remission or low disease activity
- ✓Disease-modifying antirheumatic drugs (DMARDs) initiated early in RA — methotrexate first-line
- ✓Biologic DMARDs (anti-TNF, anti-IL-6, JAK inhibitors) when csDMARD inadequate
- ✓Hydroxychloroquine and low-dose prednisolone for SLE; immunosuppressives for organ-threatening disease
- ✓Analgesia stepped approach: paracetamol → NSAIDs → opioids (short-term); topical agents in OA
What to Do Now
- Learn your personal risk factors for Ankylosing Spondylitis (family history, age, lifestyle)
- Attend regular health check-ups and screening tests appropriate for your age and risk
- Track new or changing symptoms, especially those associated with Ankylosing Spondylitis
- Use our AI symptom checker to assess whether your symptoms fit an early Ankylosing Spondylitis pattern
- Discuss preventive strategies and early monitoring with your GP
- Build a personalised management plan with your GP or specialist
- Adhere consistently to prescribed medications — do not stop without medical advice
- Adopt a Ankylosing Spondylitis-appropriate diet (anti-inflammatory, low-glycaemic, or disease-specific)
Medications Used in Ankylosing Spondylitis
Adalimumab is a TNF inhibitor biologic that blocks tumor necrosis factor-alpha to reduce inflammation in rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Etanercept is a TNF inhibitor biologic that blocks tumor necrosis factor-alpha to reduce inflammation in rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Infliximab is a TNF inhibitor biologic that blocks tumor necrosis factor-alpha to reduce inflammation in rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Golimumab is a TNF inhibitor biologic that blocks tumor necrosis factor-alpha to reduce inflammation in rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Certolizumab is a TNF inhibitor biologic that blocks tumor necrosis factor-alpha to reduce inflammation in rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Non-Pharmacological Management
- •Physical therapy: joint protection, range-of-motion exercises, strengthening — essential in OA and RA
- •Weight management: reduces mechanical load on hips/knees; reduces systemic inflammation
- •Occupational therapy: joint protection aids, assistive devices, workplace adaptations
- •Hydrotherapy and aquatic exercise: low-impact joint rehabilitation in OA
- •Dietary: Mediterranean diet reduces RA disease activity; omega-3 supplementation may reduce inflammation
- •Smoking cessation: major independent risk factor for RA initiation and worse disease course
- •Sun protection in SLE (UV can trigger flares)
Treatment Goals
Monitoring Parameters
- ◆Disease activity scores: DAS28 (RA), BASDAI/ASDAS (SpA), SLEDAI (lupus) — at 1, 3, 6 months
- ◆Shared care monitoring for methotrexate: FBC, LFTs monthly × 6, then every 3 months
- ◆Anti-TNF monitoring: TB screening (IGRA) before initiation; LTBI prophylaxis if positive
- ◆Bone mineral density: DEXA scan at baseline and every 2 years on long-term corticosteroids
- ◆Anti-dsDNA and complement (C3/C4) in SLE flare surveillance
- ◆Opthalmology: hydroxychloroquine retinopathy screening annually after 5 years use
Red Flags — When to Escalate
- ⚠Any of the characteristic symptoms of Ankylosing Spondylitis — even mild — in a high-risk individual
- ⚠Progressive worsening of early warning signs over weeks
- ⚠Laboratory abnormalities (e.g., blood sugar, inflammatory markers) without full symptoms
- ⚠Unexplained weight loss, night sweats, or fatigue persisting >2 weeks
- ⚠Strong family history of Ankylosing Spondylitis combined with new relevant symptoms
- ⚠Sudden worsening of Ankylosing Spondylitis symptoms despite established treatment
Escalation Criteria
- →Inadequate response to methotrexate at 3 months → add hydroxychloroquine/sulfasalazine or switch to biologic
- →Lupus nephritis → high-dose prednisolone + mycophenolate or cyclophosphamide
- →Vasculitis with organ involvement → IV methylprednisolone + cyclophosphamide or rituximab
- →Septic arthritis: urgent joint aspiration + IV antibiotics; surgical washout if joint destruction
Special Populations
Clinical Insights
Compare With Similar Conditions
Not sure about your symptoms?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant treatment pathways.
Use AI Symptom Checker →